Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

- Roos, Izanne, Hughes, Stella, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, McDonnell, Gavin, Soysal, Aysun, Jensen, AV, Rasmussen, PV, Svendsen, KB, Barzinji, I, Nielsen, HH, Sejbæk, T, Prakash, S, Stilund, MLM, Weglewski, A, Malpas, Charles B., Issa, NM, Kant, M, Sellebjerg, F, Gray, O, Magyari, M, Kalincik, T, MSBase Study GroupDanish MS Registry Study Group,, Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

- Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette